OUR MISSION

At Taiho Oncology our mission is to improve the lives of patients with cancer, their families, and their caregivers.

WHO WE ARE

Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of antimetabolic and selectively targeted anti-cancer agents is led by a world-class clinical development organization.

Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada.

Click to learn more about our products and pipeline.

Play Video 04:52

Taiho Oncology - Overview by CEO Tim Whitten

Backed by a Strong Heritage

Taiho Oncology, Inc. is the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., and an indirect subsidiary of Otsuka Holdings Co., Ltd., which contains more than 180 companies, with over 47,000 employees, in 30 countries worldwide. The Otsuka Group of companies, whose origins date back to 1921, aims to contribute to the health of people around the world. Taiho Oncology Inc. is the North American oncology commercial organization for the Otsuka Pharmaceuticals Co., Ltd.

Taiho Oncology logo

Taiho Oncology Inc. has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents.

The anti-cancer drug LONSURF (trifluridine and tipiracil) was approved in September 2015 by the FDA, and was introduced in the U.S. market by Taiho Oncology in October 2015.

Established in 2002, in New Jersey, United States, as a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd.

Taiho Pharmaceutical Co., Ltd. Logo

A specialty pharma company, focusing on drug discovery, preclinical research, clinical development, and building a network comprising of production, marketing, research & development in the fields of oncology, allergy and immunology, and urology.

In the company’s primary field of oncology, Taiho Pharmaceutical carries out global development of its mainstay anticancer agents in Japan, the US, Europe, and Asia.

The company also offers consumer health care products including nutritive energy drinks and herbal digestive support drinks.

Established in 1963, in Japan, as a subsidiary of Otsuka Holdings Co., Ltd.

For more information, visit www.otsuka.com/en

Our Identity

Taiho Oncology corporate symbol

THE SYMBOL

Our corporate identity was designed to reflect the organization’s guiding principles and to inspire feelings of natural energy, vitality, youth, and vigor.

The main concept of the Taiho Oncology logo is that of vital energy, with an emphasis on the energy produced by Mother Nature. This refers to the natural energy that puts forth a tree, which then grows a robust trunk, extends a branch, makes a flower bloom, and then bears fruit. The logo also captures the harmony between earth and the sun—the source of all growth and vitality on earth. This is a symbol of vitality from ancient times.

The “T” represents the initial letter of Taiho, and the power of nature is expressed by the fact that the logo is hand-drawn.

THE COLORS

Red is used to portray our company’s energy, vitality, and liveliness. The sepia (brown), an ecological color, represents human beings on earth and the intention of natural symbiosis. The yellow conveys that this is a new company, overflowing with youth and vigor.

History of Taiho